Adage Capital Partners
SWTX

Adage Capital Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Adage Capital Partners’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-150,000
Closed -$4.28M – 1039
2022
Q3 		$4.28M Sell
150,000
-425,000
-74% -$12.2M 0.01% 801
2022
Q2 		$14.2M Sell
575,000
-1,300,666
-69% -$47.6M 0.03% 573
2022
Q1 		$106M Buy
1,875,666
+1,299,214
+225% +$74.3M 0.2% 108
2021
Q4 		$35.7M Sell
576,452
-189,466
-25% -$12.5M 0.06% 311
2021
Q3 		$48.6M Buy
765,918
+202,450
+36% +$15.6M 0.1% 217
2021
Q2 		$46.4M Sell
563,468
-4,467
-0.8% -$339K 0.09% 224
2021
Q1 		$41.8M Buy
567,935
+273,935
+93% +$21.5M 0.09% 245
2020
Q4 		$21.3M Buy
+294,000
New +$18.9M 0.05% 404

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners's SWTX Position: Q4 2022 in Review

Adage Capital Partners sold out of SpringWorks Therapeutics (SWTX) in Q4 2022, closing a stake of 150,000 shares — an estimated $4.28M sold.

Adage Capital Partners first reported a position in SWTX in Q4 2020 and held it in 8 quarters. The position peaked at $106M in Q1 2022. 137 funds tracked by Wall St. Rank hold SWTX as of Q4 2022.

  • Adage Capital Partners reported no remaining SpringWorks Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Adage Capital Partners sold 150,000 SpringWorks Therapeutics shares in Q4 2022, an estimated $4.28M.
  • Adage Capital Partners first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 8 quarters.
  • Adage Capital Partners's SpringWorks Therapeutics position peaked at $106M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2022.

Based on Adage Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.